{
  "metadata": {
    "claims_file": "data/claims/Flublok_Claims.json",
    "documents": [
      "FlublokPI"
    ],
    "total_claims": 9,
    "started_at": "2025-07-29T10:50:11.372179",
    "completed_at": "2025-07-29T10:51:33.664766"
  },
  "claims": {
    "claim_000": {
      "claim_id": "claim_000",
      "claim": "Flublok ensures identical antigenic match with WHO- and FDA-selected flu strains.",
      "started_at": "2025-07-29T10:50:11.372198",
      "documents": {
        "FlublokPI": {
          "document": "FlublokPI",
          "agents_run": [
            {
              "agent": "supporting_evidence",
              "success": true,
              "timestamp": "2025-07-29T10:50:17.702731"
            }
          ],
          "final_judgment": null,
          "success": true
        }
      },
      "completed_at": "2025-07-29T10:50:17.702753"
    },
    "claim_001": {
      "claim_id": "claim_001",
      "claim": "Flublok contains 3x the hemagglutinin (HA) antigen content of standard-dose flu vaccines, which has been linked to greater immunogenicity vs standard-dose flu vaccines.",
      "started_at": "2025-07-29T10:50:17.702780",
      "documents": {
        "FlublokPI": {
          "document": "FlublokPI",
          "agents_run": [
            {
              "agent": "supporting_evidence",
              "success": true,
              "timestamp": "2025-07-29T10:50:23.522778"
            }
          ],
          "final_judgment": null,
          "success": true
        }
      },
      "completed_at": "2025-07-29T10:50:23.522796"
    },
    "claim_002": {
      "claim_id": "claim_002",
      "claim": "Cell- and egg-based flu vaccines have the potential to develop mutations during production, which may reduce their effectiveness.",
      "started_at": "2025-07-29T10:50:23.522828",
      "documents": {
        "FlublokPI": {
          "document": "FlublokPI",
          "agents_run": [
            {
              "agent": "supporting_evidence",
              "success": true,
              "timestamp": "2025-07-29T10:50:26.802722"
            }
          ],
          "final_judgment": null,
          "success": true
        }
      },
      "completed_at": "2025-07-29T10:50:26.802767"
    },
    "claim_003": {
      "claim_id": "claim_003",
      "claim": "Recombinant technology leads to a broader immune response that may provide cross-protection, even in a mismatch season.",
      "started_at": "2025-07-29T10:50:26.802804",
      "documents": {
        "FlublokPI": {
          "document": "FlublokPI",
          "agents_run": [
            {
              "agent": "supporting_evidence",
              "success": true,
              "timestamp": "2025-07-29T10:50:32.673154"
            }
          ],
          "final_judgment": null,
          "success": true
        }
      },
      "completed_at": "2025-07-29T10:50:32.673221"
    },
    "claim_004": {
      "claim_id": "claim_004",
      "claim": "Vaccination with a higher-dose recombinant flu vaccine may induce a more robust antibody response than egg-based standard-dose vaccines.",
      "started_at": "2025-07-29T10:50:32.673282",
      "documents": {
        "FlublokPI": {
          "document": "FlublokPI",
          "agents_run": [
            {
              "agent": "supporting_evidence",
              "success": true,
              "timestamp": "2025-07-29T10:50:43.764057"
            }
          ],
          "final_judgment": null,
          "success": true
        }
      },
      "completed_at": "2025-07-29T10:50:43.764076"
    },
    "claim_005": {
      "claim_id": "claim_005",
      "claim": "Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
      "started_at": "2025-07-29T10:50:43.764113",
      "documents": {
        "FlublokPI": {
          "document": "FlublokPI",
          "agents_run": [
            {
              "agent": "supporting_evidence",
              "success": true,
              "timestamp": "2025-07-29T10:50:51.697977"
            }
          ],
          "final_judgment": null,
          "success": true
        }
      },
      "completed_at": "2025-07-29T10:50:51.698018"
    },
    "claim_006": {
      "claim_id": "claim_006",
      "claim": "Flublok is produced using a novel production platform in which recombinant HA is expressed in insect cells using a baculovirus expression vector system (BEVS).",
      "started_at": "2025-07-29T10:50:51.698075",
      "documents": {
        "FlublokPI": {
          "document": "FlublokPI",
          "agents_run": [
            {
              "agent": "supporting_evidence",
              "success": true,
              "timestamp": "2025-07-29T10:51:06.807457"
            }
          ],
          "final_judgment": null,
          "success": true
        }
      },
      "completed_at": "2025-07-29T10:51:06.807491"
    },
    "claim_007": {
      "claim_id": "claim_007",
      "claim": "Recombinant HA antigens produced using BEVS have been shown to induce significantly higher levels of broadly cross-reactive antibodies against highly conserved regions of HA compared with egg-derived vaccines.",
      "started_at": "2025-07-29T10:51:06.807554",
      "documents": {
        "FlublokPI": {
          "document": "FlublokPI",
          "agents_run": [
            {
              "agent": "supporting_evidence",
              "success": true,
              "timestamp": "2025-07-29T10:51:13.405267"
            }
          ],
          "final_judgment": null,
          "success": true
        }
      },
      "completed_at": "2025-07-29T10:51:13.405284"
    },
    "claim_008": {
      "claim_id": "claim_008",
      "claim": "Flublok contains 45 micrograms (mcg) of HA per strain vs 15 mcg of HA per strain in a standard-dose influenza vaccine.",
      "started_at": "2025-07-29T10:51:13.405306",
      "documents": {
        "FlublokPI": {
          "document": "FlublokPI",
          "agents_run": [
            {
              "agent": "supporting_evidence",
              "success": true,
              "timestamp": "2025-07-29T10:51:33.664742"
            }
          ],
          "final_judgment": null,
          "success": true
        }
      },
      "completed_at": "2025-07-29T10:51:33.664759"
    }
  },
  "summary": {
    "total_claim_document_pairs": 9,
    "successfully_processed": 9,
    "processing_rate": 1.0,
    "judgment_distribution": {
      "strongly_supported": 0,
      "supported": 0,
      "weakly_supported": 0,
      "unsupported": 0
    }
  }
}